BCTX earnings analysis
What we found in BCTX's 10-Q: the parts that mattered, the offsets in the same document, and what the company said about what comes next.
Our reading of the filing · Free to read, no account needed
BriaCell Therapeutics reported no revenue for Q2 2026 alongside a diluted EPS loss of $0.99, showing a mitigating trend from a loss of $16.42 in Q2 2025. The company significantly increased its research and development spending to support ongoing clinical studies, with cash reserves of $29.9 million remaining strong post-public offering. Despite these improvements, the company continues to grapple with high operating losses and substantial reliance on future financing.
The parts that mattered.
Pulled out of the filing itself, with the figures the company reported.
- Improvement in EPS
- Diluted EPS loss improved to -$0.99 from -$16.42 a year ago.
- Strong Cash Reserves
- Cash and cash equivalents amount to $29.9 million post recent financing.
- Increased Clinical Investment
- R&D expenses rose to $5.97 million from $4.81 million year-over-year.
- Positive Cash Flow from Financing
- Generated approximately $30 million in gross proceeds from a public offering.
- Expanded Clinical Activities
- Clinical trial expenses up to $4.35 million, driven by pivotal Phase 3 study of Bria-IMT.
- Working Capital Improvement
- Working capital increased to $21.8 million from $15.9 million year-over-year.
And the other side of it.
The offsets in the same document — the things a summary that only listed the good news would have left out.
- Continued Operating Losses
- Net loss for Q2 2026 was $7.24 million, up from $6.22 million year-over-year.
- High Cash Burn Rate
- Operating cash flow used rose to $22.69 million for the nine-month period.
- Reliance on Future Financing
- Company's ability to continue as a going concern is increasingly uncertain.
What they reported.
What the company itself reported, taken out of the document.
- Earnings per share
- $-0.99
What they said about what is next.
Outlook deferred to earnings press release / call.
The filing reads about the same as the one before it.
What came before.
- 10-Q · March 10, 2026
- BriaCell reported no revenue and a net loss attributable to BriaCell of $7,221,820 for the quarter ended January 31, 2026 (vs. $6,291,420 in prior-year quarter). Cash increased materially to $29,903,628 following net…
- 10-Q · December 11, 2025
- BriaCell reported no revenue and a wider quarterly net loss of $8,278,328 for the three months ended October 31, 2025, versus $5,829,276 in the prior-year quarter, driven by a sharp increase in R&D spending as the…
- 10-Q · June 16, 2025
- BriaCell reported a Q3 net loss of $6,224,929 (BriaCell attributable loss $6,126,902) and diluted EPS of $(1.64), reversing a prior-year quarterly income of $1,692,242 (EPS $1.61). Cash improved sharply to $12,460,253…
- 10-Q · December 16, 2024
- BriaCell reported a net loss of $5,829,276 (net loss per share – basic $0.22) for the three months ended October 31, 2024, an improvement in operating loss to $5,152,832 from $8,503,028 a year earlier. The company…
This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.
Read the next one first.
We read every filing BCTX makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.
Cancel anytime · Month to month · Switch tiers whenever